At the news
? BULLISHIMPACT 8/10 PRESS-RELEASE filed Aug 26, 2026 at 12:59 ET
Revolution Medicines received FDA approval for RASONQUE (daraxonrasib) for metastatic pancreatic adenocarcinoma after at least one prior therapy. The Phase 3 RASolute 302 trial showed a 60% reduction in death risk (HR 0.40) and median OS of 13.2 months vs 6.7 months for chemotherapy. This is the first approved targeted RAS inhibitor for pancreatic cancer, a major commercial opportunity for RVMD given the high unmet need and large patient population (~55,000 annual US diagnoses).
- FDA approved RASONQUE (daraxonrasib) for metastatic pancreatic adenocarcinoma after at least one prior systemic therapy
- Phase 3 RASolute 302 trial showed 60% reduction in risk of death (HR 0.40; p<0.0001) vs chemotherapy
- Median overall survival 13.2 months with RASONQUE vs 6.7 months with chemotherapy
- Median progression-free survival 7.2 months vs 3.6 months (HR 0.49; p<0.0001)
Before · The news · First close · A day later · A week later
Replay the market's reaction
Step through every 5 minutes around the news, then see how it compares with similar events.
Subscribe for Full Access